Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M. Syeda, David Polsky, A. Hauschild et al.|The Lancet Oncology|2025Cited by 28
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.Mahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|Journal of Clinical Oncology|2023Cited by 6
Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238Mahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|Clinical Cancer Research|2024Cited by 0